These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30741056)

  • 1. Enhanced antitumor efficacy and attenuated cardiotoxicity of doxorubicin in combination with lycopene liposomes.
    Zhu J; Hu Q; Shen S
    J Liposome Res; 2020 Mar; 30(1):37-44. PubMed ID: 30741056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of doxorubicin-dihydroartemisinin prodrug/TEPP-46 nano-liposomes for improving antitumor and decreasing cardiotoxicity in B16-F10 tumor-bearing mice.
    Jin Q; Zhou X; Niu X; Ping C; Dong X; Duan D; Wang R; Chen Y; Pan F; Yang F; Yang X; Zhang G; Wang R; Zhang S; Ren G
    Colloids Surf B Biointerfaces; 2024 Sep; 241():113992. PubMed ID: 38833960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
    Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
    Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotin anchored nanostructured lipid carriers for targeted delivery of doxorubicin in management of mammary gland carcinoma through regulation of apoptotic modulator.
    Tripathi CB; Parashar P; Arya M; Singh M; Kanoujia J; Kaithwas G; Saraf SA
    J Liposome Res; 2020 Mar; 30(1):21-36. PubMed ID: 30741049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
    Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
    Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo.
    Zheng K; Li R; Zhou X; Hu P; Zhang Y; Huang Y; Chen Z; Huang M
    Int J Nanomedicine; 2015; 10():5327-42. PubMed ID: 26346331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
    Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
    J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lycopene liposomes: lycopene release in vitro and pharmaceutical behaviors and antioxidation in vivo].
    Tian YY; Ge L; Duan XL; Gao ZQ; Chang YZ
    Yao Xue Xue Bao; 2007 Oct; 42(10):1107-11. PubMed ID: 18229623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor delivery of liposomal doxorubicin prepared with poly-L-glutamic acid as a drug-trapping agent.
    Miatmoko A; Kawano K; Yoda H; Yonemochi E; Hattori Y
    J Liposome Res; 2017 Jun; 27(2):99-107. PubMed ID: 26982164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
    Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
    Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
    Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
    Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cationic Polymethacrylate-Modified Liposomes Significantly Enhanced Doxorubicin Delivery and Antitumor Activity.
    Wang W; Shao A; Zhang N; Fang J; Ruan JJ; Ruan BH
    Sci Rep; 2017 Feb; 7():43036. PubMed ID: 28225062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nano-liposomes of lycopene reduces ischemic brain damage in rodents by regulating iron metabolism.
    Zhao Y; Xin Z; Li N; Chang S; Chen Y; Geng L; Chang H; Shi H; Chang YZ
    Free Radic Biol Med; 2018 Aug; 124():1-11. PubMed ID: 29807160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
    Ahmed KS; Shan X; Mao J; Qiu L; Chen J
    Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
    Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
    Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
    Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
    Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E; Haeri A; Vali AM; Ostad SN; Dadashzadeh S
    J Pharm Pharm Sci; 2012; 15(4):568-82. PubMed ID: 23106959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes).
    Jain S; Patil SR; Swarnakar NK; Agrawal AK
    Mol Pharm; 2012 Sep; 9(9):2626-35. PubMed ID: 22871060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.